Operating Segments (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Operating Segments [Abstract]

Summary of segmental information

	Three Months Ended   June 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	3,160,050		$	1,099,827
BioTherapeutics		-			-
Total	$	3,160,050		$	1,099,827
Income (Loss) from Operations
Vaccines/BioDefense	$	734,120		$	302,531
BioTherapeutics		(668,260	)		(1,383,167	)
Corporate		(1,075,818	)		(954,115	)
Total	$	(1,009,958	)	$	(2,034,751	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	10,041		$	9,941
BioTherapeutics		10,564			49,866
Corporate		2,223			1,924
Total	$	22,828		$	61,731
Other Income (Expense), Net
Corporate	$	917,183		$	(1,942,943	)
Share-Based Compensation
Vaccines/BioDefense	$	24,223		$	19,344
BioTherapeutics		30,985			30,179
Corporate		145,065			87,640
Total	$	200,273		$	137,163

	Six Months Ended   June 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	5,791,037		$	1,902,141
BioTherapeutics		-			13,972
Total	$	5,791,037		$	1,916,113
Income (Loss) from Operations
Vaccines/BioDefense	$	1,052,111		$	387,212
BioTherapeutics		(1,914,682	)		(2,148,043	)
Corporate		(2,053,092	)		(1,832,187	)
Total	$	(2,915,663	)	$	(3,593,018	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	20,060		$	19,727
BioTherapeutics		20,996			98,240
Corporate		4,380			3,690
Total	$	45,436		$	121,657
Other Income (Expense), Net
Corporate	$	1,673,455		$	(4,953,998	)
Share-Based Compensation
Vaccines/BioDefense	$	52,229		$	43,936
BioTherapeutics		65,817			59,435
Corporate		218,638			175,817
Total	$	336,684		$	279,188

	As of  June 30, 2016		As of  December 31,  2015
Identifiable Assets
Vaccines/BioDefense	$	1,921,812	$	2,123,676
BioTherapeutics		63,836		76,183
Corporate		3,430,399		5,187,263
Total	$	5,416,047	$	7,387,122

	For the Years Ended December 31,
	2015			2014
Revenues
Vaccines/BioDefense	$	8,754,418		$	6,756,388
BioTherapeutics		13,972			286,628
Total	$	8,768,390		$	7,043,016
Income (Loss) from Operations
Vaccines/BioDefense	$	1,263,709		$	807,164
BioTherapeutics		(4,487,988	)		(7,674,381	)
Corporate		(3,885,997	)		(3,894,132	)
Total	$	(7,110,276	)	$	(10,761,349	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,925		$	39,625
BioTherapeutics		199,661			199,196
Corporate		7,872			6,966
Total	$	247,458		$	245,787
Other Income (Expense), Net
Corporate	$	(1,209,887	)	$	3,437,505
Share-Based Compensation
Vaccines/BioDefense	$	111,960		$	114,920
BioTherapeutics		148,244			193,926
Corporate		394,277			411,304
Total	$	654,481		$	720,150

	As of December 31,
	2015		2014
Identifiable Assets
Vaccines/BioDefense	$	2,123,676	$	1,025,220
BioTherapeutics		76,183		204,308
Corporate		5,187,263		5,724,720
Total	$	7,387,122	$	6,954,248